警报 (加拿大特征性不受控制的重症喘):过度使用口服皮质类固醇和短效β2agonist
Andréanne Côté1, Jeffrey Beach2, Jenna Reynolds2
1Québec Heart and Lung Institute - Université Laval, Québec City, Québec, Canada.
概括
许多患有严重喘的加拿大人仍然无法控制,经常过度使用口服皮质类固醇 (OCS) 和短效β2-激动剂 (SABA). 该研究强调需要更好的诊断和更早的生物使用,以改善喘管理.
科学领域:
- 肺部病理学 肺部病理学
- 现实世界的证据.
- 医疗服务研究 医疗服务研究
背景情况:
- 严重的喘影响着加拿大显著的人口,尽管有生物可用性,但许多病例仍然无法控制.
- 目前的治疗方法,如口服皮质类固醇 (OCS) 和短效β2-激动剂 (SABA),具有相当大的风险.
- 需要了解严重喘患者的治疗模式,以获得更好的患者结果.
研究的目的:
- 描述加拿大严重喘患者的人口统计.
- 分析包括OCS,SABA和生物使用在内的治疗模式.
- 为了确定治疗失控严重喘的变化.
主要方法:
- 使用纵向索赔数据进行回顾性描述性研究.
- 推导性喘诊断和严重的分类,不受控制的严重和不受控制的严重喘没有生物药物.
- 在12个月的时间内对OCS,SABA和生物声明的分析.
主要成果:
- 患有严重喘的患者有较高的OCS索赔率 (2.7-4.4 / 年).
- 很大一部分未经控制的严重喘患者 (71.8%) 不使用生物制剂.
- 观察到OCS使用的区域差异,表明护理不一致.
结论:
- 改善喘诊断和患者教育至关重要.
- 较早的专家转诊和特定区域的干预措施可以优化管理.
- 该研究主张减少OCS/SABA的依赖,并增加符合条件的患者的生物吸收.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
398
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
398
COPD: Management Using Bronchodilators and Corticosteroids
319
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
319
Antiasthma Drugs: β2-Adrenoceptor Agonists
392
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
392
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Drugs Used in Lower Respiratory Disorders: Overview
599
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
599
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K


